We have utilized a novel polyethylenimine (PEI)/DNA-bgal vector to investigate the specificity and efficiency of immunotargeting prostate-specific membrane antigen (PSMA). Coupling of the PSMA-specific monoclonal antibody, J591, to the vector was facilitated via the high-affinity interaction between phenyl(di)boronic acid and salicylhydroxamic acid molecules. Highly efficient gene delivery by this prostate cancer (PCA)-targeted J591/polyethylene glycol (PEG)/PEI/ DNA-bgal vector was demonstrated in PSMA-positive cells relative to controls, resulting in significant growth inhibition in vitro when the J591/PEG/PEI/DNA-p53 was used. Competition with free antibody resulted in about 90% reduction in both J591 internalization and bgal gene delivery, indicating specificity for PSMA-positive cells. More importantly, testing the efficiency of the J591/PEG/PEI/DNA-bgal targeting vector in an orthotopic PCA model in nude mice resulted in up to a 20-fold increase in gene delivery over the untargeted vector controls. The in vivo organ distribution profile also revealed bgal expression predominantly in the tumor, which was more than 1 log higher than the next highest level of expression in the lung. Furthermore, with the targeted vector containing the gene for yellow fluorescent protein or biotinylated J591, we further demonstrate in vivo that vector-mediated gene delivery is specific for both tumor cells and tumor-associated neovasculature in PSMA-positive tumors. These results suggest the potential for further optimization of this novel vector in the context of therapeutic gene delivery. Gene Therapy (2006) 13, 761-772.
Introduction
The greatest limiting factor to effective gene therapy is the choice of delivery vector. [1] [2] [3] Consequently, the generation of safe and effective gene delivery vectors without eliciting adverse effects at both the cellular level and in the organism as a whole is much needed. 4 Although producing high levels of transduction, viral vectors as a whole have many disadvantages for use in gene therapy, such as difficulty in construction, inability to target, toxicity and immunogenicity. 5, 6 A lot of attention has hence been placed on non-viral vectors to bypass the limitations of viral vectors. 7, 8 Non-viral vectors in the form of molecular conjugates utilize polycations like polyethylenimine (PEI) to condense and compact DNA. One advantage of PEI is its intrinsic buffering capacity over a broad pH range. [9] [10] [11] PEI/DNA complexes, like all non-viral vectors, however, have lower transfection efficiencies both in vitro and in vivo than viral vectors. [1] [2] [3] In addition, it has been widely documented that intravenous injection of a PEI/DNA vector results in the accumulation of the vector within the lungs, 12 which is a problem when the cancerous target cells are located elsewhere. One attractive solution to this dilemma is targeting the PEI/DNA vector to a tumor-specific marker for more specific delivery in vivo.
A possible prostate target that is overexpressed in prostate tumors is prostate-specific membrane antigen (PSMA). 13, 14 Prostate-specific membrane antigen is a 100 kDa transmembrane protein that was initially isolated from LnCapD prostate cancer (PCA) cells and has since been characterized as a type II integral membrane protein with a small extracellular domain. 15, 16 Although this membrane protein has been identified in prostate epithelial cells, duodenal mucosa and some proximal renal tubules, as well as prostatic endothelium, 17 the majority of extra-prostatic expression of PSMA appears to be very limited, 15 thus making it hold potential promise for tumor targeting. In order to target PSMA, an anti-PSMA monoclonal antibody (mAb), J591, has already been generated and shown cellular internalization. 18, 19 Therefore, we envisaged that a J591/PEI/DNAbgal vector could be harnessed in targeting PSMA in the prostate tumor.
In this report, we exploited the interaction between phenyl(di)boronic acid (PDBA) and salicylhydroxamic acid (SHA) molecules to couple J591 mAb to the PEI/ DNA-bgal vector. This coupling system utilizes these two small synthetic molecules as high-affinity binding components ( Figure 1 ). Stability of the complex is maintained under a wide variety of conditions and the interaction is reversible. [19] [20] [21] The strength of this interaction is similar to that of an antibody binding an antigen, and was designed with the idea that PDBA would function in a similar fashion as a hapten, while SHA would represent an anti-hapten antibody. In addition to stability, PDBA and SHA have the advantage of not stimulating an immune response from a host organism. 20, 21 We demonstrate that, using this strategy to couple J591 mAb to PEI/DNA-bgal, intravenous administration of the resulting J591 targeting vector to nude mice harboring PSMA-positive C4-2 orthotopic prostate tumors results in specific and efficient gene delivery to the tumor cells and tumor-asscociated neovascular endothelial cells as opposed to other organs. Indeed the findings in this report, coupled with our previous findings describing the targeting of CD13/ aminopeptidase N in a distant tumor in nude mice, 22 validates the simplicity, specificity and efficiency of this coupling system, thus serving as a proof of principle in maintaining the targeting integrity of the ligand. This study also represents the first demonstration of a nonviral vector that has specific and efficient targeting fidelity for PSMA when administered via the systemic route.
Results
Analysis of prostate-specific membrane antigen expression and internalization of J591 in prostatespecific membrane antigen-positive cells Initially, we analyzed PSMA expression on the panel of PCA cell lines used in our studies by Western blotting.
Probing with J591 mAb identified both LnCapD and C4-2 cells as positive, while PC3MM2, Du145, PC3 and H1299 cells are negative for PSMA ( Figure 2a) . Next, to characterize the effects of J591 antibody, it was important to verify that the antibody could be specifically internalized by PSMA-positive PCA cells. This was determined by incubating the C4-2 cell line with streptavidinbgal, J591-biotin plus streptavidin-bgal, or J591-biotin plus streptavidin-bgal and a 100-fold molar excess of J591. The PCA cell line-specific internalization of J591 resulted in an approximately 13-fold increase in bgal activity after incubation of J591-biotin plus streptavidinbgal, and about 90% decrease in bgal activity when a 100-fold molar excess of J591 was used as a competitor (Figure 2b ).
Transfection analysis of polyethylenimine/DNA-bgal in different prostate cancer lines
Before testing J591-targeted transfection on PCA cell lines, the transfection efficiency of our untargeted PEI/ DNA-bgal vector was determined with various amine to phosphate (a/p) ratios, in order to serve as a baseline for comparison to targeted vectors. This analysis was performed with the PCA cell lines, PC3MM2, PC3, LnCapD, C4-2, Du145 and the non-small-cell lung cancer cell line H1299. Overall, the highest level of transfection in all PCA cell lines was obtained at an a/p ratio of 2.7/1; so this ratio was utilized for transfection in all the cell lines tested. The mean transfection efficiencies for the cell lines transfected with the PEI/DNA-bgal vector as determined by histochemical staining for bgal expression were 50, 48, 46, 40, 38 and 36% in PC3MM2, H1299, PC3, LnCapD and C4-2. The transfection efficiencies were however higher in PSMA-positive cells and decreased with decreasing PSMA status when J591/PEI/DNA-bgal was used, resulting in 75, 70, 60, 44, 40 and 38% efficiencies in LnCapD, C4-2, PC3, Du145, PC3MM2 Figure 1 Phenyl(di)boronic acid-salicylhydroxamic acid coupling procedure. The J591 antibody is coupled to PEI in our novel vector by attaching PDBA to the antibody via a PEG linker, which acts as a hydrolysable spacer, and SHA to PEI and bgal, allowing for a selfassembling linkage between PDBA and SHA.
Targeting PSMA with J591-mediated conjugate S Moffatt et al and H1299, respectively (Figure 3a and b) . To obtain reliability in the assay protocol for all the cell lines due to the extreme difficulty in transfecting C4-2 cells, bgal expression in lysates from all cell lines tested was also determined using a Galacto-Light chemiluminescent reporter assay (Tropix) and the results normalized to yield relative light units (RLU) per milligram protein of the respective cells (Figure 3c and d). With this assay, the pattern of expression did not differ from that of the histological staining. We next proceeded to generate a J591 targeted version of the PEI/DNA-bgal vector to test for enhanced transfection in vitro and in vivo.
Efficient and specific transfection of J591/polyethylene glycol/polyethylenimine/DNA-bgal and J591/ polyethylene glycol/polyethylenimine/DNA-p53 in prostate-specific membrane antigen-positive cells
In order to generate the J591 targeting vector, PDBApolyethylene glycol (PEG) was coupled to J591 to yield PDBA-PEG-J591. The actual number of PDBA molecules per J591 utilized in the coupling reaction was deduced from the formula provided by the manufacturer (Prolinx) as summarized in Table 1 . The 5:1 PDBA:J591 ratio was then combined with SHA-PEI/DNA-bgal to form a J591 targeting vector, J591/PEG/PEI/DNA-bgal. Following the coupling reaction, enzyme-linked immunosorbent assay (ELISA) was performed not only to verify PDBA binding to J591, but also to ascertain that the PDBA-PEG-J591 conjugate was still capable of binding SHA molecules. This was confirmed by combining SHA to a range of PDBA-PEG-J591 conjugates from 10 ng to as high as 1 mg, with the highest level of optical density (OD) 450 reading coming from 50 ng of PDBA-PEG-J591. In addition, this binding was shown to be specific due to the dramatic decrease in PDBA-PEG-J591 binding to SHA upon addition of a 100-fold molar excess of the free PDBA in the ELISA assay ( Figure 4a ). The specificity was further confirmed by the addition of a non-specific hamster IgG, which had no effect on the binding. Based on these results, we concluded that we had generated a PDBA-PEG-J591 conjugate that is capable of interacting with SHA to ultimately form a J591 targeting PEI/DNA vector. To further determine its targeting efficiency, J591/ PEG/PEI/DNA-bgal vector was initially incubated with the PSMA-positive PCA cell line LnCapD. There was no significant change in the transfection efficiencies of PEI/DNA-bgal, SHA-PEI/DNA-bgal or J591/PEG/ PEI/DNA-bgal in LnCapD cells. While little increases in transfection efficiency resulted from J591:vector ratios of 1, 156 and 378, there was a significant (Po0.05) surge in transfection efficiency in C4-2 cells using 756 J591:vector ratio (Figure 4b ). There was no difference, however, in transfection efficiency between PEI/DNAbgal and SHA-PEI/DNA-bgal in both cell lines (data not shown), indicating that the modification of PEI to SHA-PEI neither altered the binding to nor the transfection efficiency of the condensed DNA. While the addition of PEG to the outside of the vector reduced transfection levels due to the change in overall vector charge ( Figure  4b , lane 2), the addition of the antibody to the outside of the PEG-PEI/DNA vector facilitated a higher level of gene expression (Figure 4b , lane 3). Little increases in the levels of bgal expression above those obtained with the controls was observed with J591:vector ratios up to 378, followed by a dramatic and significant surge in transfection efficiency when 756:1 ratio was used. This was followed by a significant (Po0. Targeting PSMA with J591-mediated conjugate S Moffatt et al specific uptake by PSMA, competition was performed by incubating the 756:1 J591:vector ratio along with a 100-fold molar excess of J591 on C4-2 cells. As shown in Figure 4b , this resulted in about 90% reduction in the level of transfection, thereby indicating specificity. To confirm this, addition of excess non-specific hamster IgG (hIgG) had no effect on the level of transfection.
To further confirm if this delivery was occurring specifically through PSMA, this same analysis was performed using the PSMA-negative PCA cell line PC3MM2 (data not shown), and, in these cells, there was no significant change (P ¼ 0.06) in the levels of transfection between the cells treated with controls and those incubated with vector combined with increasing amounts of PDBA-J591.
To further ascertain that this targeting vector was specific for PSMA-positive cells, we coupled pCEP4/p53 plasmid DNA (which encodes for p53 protein) to PEI in the targeting vector, yielding J591/PEG/PEI/DNA-p53, and analyzed its effect on proliferation of both PSMApositive and -negative cells at different time points. Using this vector, efficient cell killing resulting in significant (P ¼ 0.03) growth inhibition was observed in C4-2 cells after transfection of the targeting vector containing p53 (Figure 5a ) as compared to the PSMAnegative PC3MM2 cells (Figure 5b ). Moreover, cell killing with PEI/DNA-bgal or PEI/DNA-p53 coupled to hIgG controls was similar and comparatively insignificant. Based on these in vitro results and high levels of transfection at a J591:vector ratio of 756:1, we next tested bgal Activity was determined 24 h after transfection by both histological staining and normalization to bgal activity using a Tropix bgal detection kit (n ¼ 5). The number of PDBA molecules was calculated based on the formula provided by Prolinx Product Manual. The absorptivity of PDBA at 260 nm is 4.0 (when the concentration is expressed as mM). The actual moles of conjugated PDBA per mole of protein can be estimated quantitatively by comparing the absorbance at 260/280 nm of unmodified protein (P) to that of modified protein (PDEA-P). An increase in the absorbance at this wavelength is due to the PDBA addition. Figure 6b ). In addition, bgal expression in C4-2 tumors from animals injected with the J591/PEG/ PEI/DNA-bgal vector was also significantly higher than those from animals treated with SHA-PEI/DNA-bgal alone. This analysis was performed to eliminate the possibility that the increased transfection was due to SHA-PEI/DNA-bgal vector, which would result if the PDBA-SHA linkage between J591 and the PEI/DNAbgal vector disassembled in vivo. To further support J591-mediated targeting, analysis of the lungs of the C4-2-implanted animals revealed no significant increase (P ¼ 0.06) in bgal expression relative to control in the lungs of animals injected with PEI/DNA-bgal, SHA-PEI/DNA-bgal or J591/PEG/PEI/DNA-bgal vectors. Furthermore, conjugation of PEI/DNA-bgal vector with a control hIgG was not associated with an increase in gene expression relative to the J591/PEG/PEI/DNAbgal targeting vector, thereby adding another line of specificity. Although bgal expression in the C4-2 tumors of J591/PEG/PEI/DNA-bgal-injected animals increased more than a log higher than other treatment groups, there was no comparable increase of bgal expression in the lungs of these animals. These findings further imply specificity of the J591/PEG//PEI/DNA-bgal vector for the C4-2 prostate tumor.
To further confirm the in vivo targeting efficiency of the J591 vector, yellow fluorescent protein (YFP) was substituted for bgal in the targeting vector. This J591/ PEG/PEI/DNA-YFP vector was administered intrave- Targeting PSMA with J591-mediated conjugate S Moffatt et al log higher than the next highest level of expression in the lung ( Figure 9 ). In addition, none of the other organs that were analyzed produced levels that were higher than those obtained in the lung, with most of the levels being as much as 30-fold lower than levels obtained in the tumor. In contrast, the highest level of gene expression by the non-targeting controls was in the tumor, but only about 10% of that obtained with the targeting vector (data not shown). This provided further proof that the J591 targeting vector was mediating very specific and high-level gene delivery to the prostate tumor following intravenous administration. Targeting PSMA with J591-mediated conjugate S Moffatt et al in J591-mediated internalization when the targeting vector was competed with excess mAb. Taking into consideration the fact that untargeted PEI/DNA vectors generally produce lower transfection levels as compared to viral vectors, 23, 24 transfection mediated by our PEI/ DNA vector (573 Â 10 6 RLU/mg of protein) on PCA cells, was also shown to be much higher than published reports ranging from 1 Â 10 4 25 to undetectable amounts of protein 26 at similar a/p ratios, but lower than those of viral vectors. Furthermore, use of our novel PEI/DNA vector at a low a/p ratio of 2.7/1 produced low-toxicity transfections, and this was between 30 and 40 times higher than levels obtained with the commonly used, more toxic 9:1 a/p ratio. We therefore hypothesized that using this PEI/DNA formulation to target PSMA with J591 antibody should at minimum increase specificity of the PEI/DNA vector for a distant tumor.
Prior to this however, it was important to demonstrate by ELISA the strong affinity of the PDBA-PEG-J591 conjugate for SHA molecules. Even more importantly, transfection with the targeting vector, J591/PEG/PEI/ DNA-bgal, on the PSMA-positive cell line C4-2 revealed increased transfection levels as compared to the untargeted vector. The optimum amounts and moiety of J591 coupled to the PDBA in the complex was however essential in facilitating a high gene expression. Increasing the ratio of J591 molecules to PDBA resulted in slight increases in gene expression (P ¼ 0.05, Mann-Whitney U-test) until it peaked at 756:1 ratio. Similar to the in vitro results, J591 ratios lower or higher than 756 resulted in lower levels of gene expression in vivo (data not shown), further emphasizing the need to optimize the ratios of the coupling components in this type of interaction. Secondly, competition experiments with excess free mAb indicated the specificity of the J591/PEG/PEI/DNA-bgal vector for PSMA. It is worth noting that the high level of PSMA on these cells was critical in producing significant levels of in vitro transfection by the J591 mAb. Although the overall transfection levels of the C4-2 cell line increased relative to controls, this increase was not dramatic, the highest being approximately 15-fold increase over the untargeted controls at a ratio of 756 molecules of J591 per vector. Results such as this are however not uncommon. Previous studies in our laboratory and others 22, 27, 28 have indicated that this lack of increase is typically due to the limitations of the in vitro transfection conditions in that no external forces were used to increase vector to cell interactions, as one may see in vivo following an intravenous administration, which often leads to uncorrelated in vitro and in vivo results. [29] [30] [31] Nevertheless, this finding implies the specificity of targeted transfection through PSMA, and not through non-specific interactions. As further evidence of PSMA receptor targeting, transfection of the PSMAnegative PCA cell line PC3MM2 with the targeting vector did not result in any significant change in transfection levels as compared to the untargeted vector (data not shown).
The use of the 25-kDa PEI in this formulation was also critical, based on its polycationic and branched structure that allows for a more efficient DNA binding, condensation and intrinsic endosmolytic activity than highermolecular-weight PEIs. Additionally, the 2.7/1 a/p ratio of PEI/DNA used in the present in vitro and in vivo studies has a marginally positive z potential (+5.772.1 mV), and thus should minimally interact with complement and other protein species, making it ideal for in vivo delivery. This may also contribute to the preferential gene expression in tumor tissue we observed after the intravenous administration of the PEI/DNA vector formulations, which agrees with recent observations that a PEI/DNA vector with a positive z potential is likely to predominantly mediate lung transfection, whereas formulations with near neutral z potentials such as we used selectively transduces tumors. 32 The J591 targeting ligand formulation with 30% PEG and 50% dextrose increased the particle size (80979.1 nm) and decreased gene delivery when more or less than 756 J56 molecules per vector were utilized, indicating that a critical number of J591 molecules is needed for efficient gene delivery. Interestingly, the z potential of the J591/ PEG/PEI/DNA-bgal targeting vector z +28.573.10 and a size of 80979.1 nm resulted in the most efficient formulation for targeting the prostate tumors, implying that a more critical factor in the formulation was the overall charge of the conjugate. Although a more empirical study should be carried out to ascertain this, it is possible that a low positive z potential of the targeting vector may favor better interaction with integrins that can be increased in proliferating tumor cells, leading to endocytosis and increased gene delivery.
Targeted vector administration via tail vein in mice bearing PSMA-positive C4-2 tumors resulted in approximately 20-fold increase in bgal expression over the untargeted vectors and 50-fold increase over HEPES buffer control. No significant difference in bgal expression was detected in animals bearing PSMA-negative PC3MM2 tumors, which were injected with targeted or untargeted vector. We also noted that PEG-encapsulated vector without the PSMA antibody had reduced levels of gene expression, but was elevated upon bio-conjugation with J591. The addition of J591 possibly restored the overall vector charge and increased the specificity and retention times in the tumor. These findings make our targeting strategy very attractive in the light of reports showing little or no transfection of tumor cells in xenograft tumor models when using other systemically administered PEI/DNA formulations. [32] [33] [34] Interestingly, Prostate-specific membrane antigen is a unique antiangiogenesis target because it is selectively and consistently expressed in non-prostatic tumorassociated neo-vasculature, but not in normal vessels in benign tissue. This is in contrast to other endothelial cell targets such as vascular endothelial growth factor receptors, integrin avb3, CD34 and Tie receptors, which are normally expressed in normal vasculature and are upregulated in tumor neo-vasculature. [36] [37] [38] The significance of this, coupled with the intense detection of targeting predominantly on the neovasculature regarding the function of PSMA, may lie in therapeutic applications. Humanized anti-PSMA antibodies could be used to deliver a variety of agents aimed at destroying neo-vasculature, ranging from conventional cellular toxins to peptide-based pro-drug activators. The present study also confirms results from previous analyses with respect to the immunohistochemical detection of PSMA in primary and metastatic PCA. 39 Furthermore, the intensity of PSMA detection and targeting in the neovasculature of C4-2-generated tumors when explanted after a week, in contrast to benign vascular tumors, may be that in these tumors the endothelium itself is altered and presumably not stimulated by angiogenic factors. This may also be a possible indication of increasing pathological grade in PSMA-positive tumors, which would be important in the context of therapeutic gene delivery to patients with advanced PCA.
As novel findings, we have demonstrated that our PEI/DNA vector formulation, with a low a/p ratio of 2.7/1, is effective at transfecting various PCA cell lines with high efficiency and little visible toxicity. In addition, the results from these experiments are the first to demonstrate the ability of a PEI/DNA vector to target PSMA via the J591 mAb. Furthermore, these studies are also the first to show that a PDBA-SHA linkage can efficiently be used to couple J591 mAb for targeting PSMA in vivo. Lastly, we have demonstrated that our J591 targeted PEI/DNA vector is capable of increasing transfection levels, as compared to untargeted PEI/ DNA, in prostate tumors after intravenous administration. Our study represents the creation of a vector that holds considerable promise for systemic delivery of therapeutic genes to tumor cells and/or tumor endothelium. Indeed, the targeting vector with p53 tumor suppressor gene was able to significantly kill PSMApositive cells over and beyond that of PSMA-negative cells. Further studies in optimizing the use of this vector is required, but it clearly provides a basis for further development of a non-viral, targeted DNA delivery system that can be applied to PCA gene therapy. Consequently, we are currently performing comprehensive in vivo studies of delivering potential therapeutic genes to prostate tumors via this novel vector.
Materials and methods

Cells and culture conditions
H1299 (non-small-cell lung cancer) was cultured in RPMI with 5% FBS (Gibco). The PCA cell lines C4-2, LnCapD, PC3 and PC3-MM2 were cultured in RPMI with 10% FBS supplemented with 1% antibiotic-antimycotic (penicillin-streptomycin-amphotericin, GibcoBRL) and 1% L-glutamine, whereas Du145 was grown in RPMI with 10% FBS supplemented with 1% penicillin-streptomycin and 1% L-glutamine. All cells were cultured in a 371C incubator with 5% CO 2 .
Phenyl(di)boronic acid-PEG-J591 formation
The addition of PEG (Sigma, Mr ¼ 3000) as a spacer between PDBA and J591 was done in a stepwise manner by first generating PDBA-PEG. About 300 mg of oamino-a-carboxyl PEG (Sigma) was re-suspended in 0.1 M NaHCO 3 to a final concentration of 2 mg/ml. A 10 mM stock of PDBA-x-N-hydroxysuccinimide (NHS) (Prolinx Inc., Bothell, WA, USA) was made in N-N dimethylformyl amine. A molar ratio of 5:1 (optimized ratio for our transfection studies) of PDBA to PEG was produced by adding 4.4 ml of PDBA-x-NHS solution to the PEG solution. The sample was then dialyzed using a 1000-Mw membrane (Spectrum Laboratories) for 48 h at 41C against 20 mM HEPES buffer in the cold to yield PDBA-PEG. For PDBA-PEG-J591 formation, J591 was first warmed in 371C for 5 min to activate the antibody. J591 antibody (300 mg) was then reacted with 0.1 M NaHCO 3 in a final volume of 250 ml. Following this, 1.3 ml of 0.1 M DTT solution was added for 10 min in a 371C water bath to reduce disulfide bond formation. The DTT was then removed with Ultrafree-MC filter unit (Millipore). In all, 300 mg of the 5:1 PDBA:PEG ratio was then placed in a solution of 0.1 M 2-[N-morpholino]ethane-sulfonic acid (Sigma), pH 6.0, and 0.5 M NaCl, and the final volume was brought up to 300 ml with distilled water. To activate the PEG for coupling to J591, 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide (Sigma) and NHS (Sigma) were added to final concentrations of 2 and 5 mM, respectively, allowed to react at room temperature for 15 min, and the reaction terminated with b-mercaptoethanol at a final concentration of 20 mM. Finally, 150 mg of J591 (1 mg/ml) was then combined with the PDBA-PEG solution and allowed to proceed for 2 h at room temperature, after which dialysis was performed for 48 h with 6000-8000 Mw cutoff membrane. Initially, three different estimated PDBA:J591 ratios of 200:1, 20:1 and 2:1 were generated and absorbance measured before and after PDBA addition. The actual moles of conjugated PDBA per mole of J591 protein was then estimated quantitatively using the formula by Prolinx, by comparing the absorbance at 260 nm of unmodified protein (P) to modified protein (PDBA-P) as described in Table 1 . An
Targeting PSMA with J591-mediated conjugate S Moffatt et al increase in the absorbance at this wavelength is due to the PDBA addition. With this, actual ratios were then determined to be 12.5:1, 5:1 and 1.4:1, respectively, from the initial calculation. The molar ratios of J591 per vector were then calculated in a similar manner.
Plasmids and cell proliferation assay
The plasmid pCMVbgal contains the Escherichia coli bgal gene under the control of the cytomegalovirus enhancer and promoter. Plasmid pCEP4/p53 was generated by subcloning the 1.1 Kb p53 gene from plasmid pCMVp53 into the BamH1 site of pCEP4 episomal expression plasmid (Invitrogen, Carlsbad, CA, USA), upstream of the CMV promoter. All plasmids were isolated by an alkaline-SDS lysis method, checked for the presence of endotoxin with a limulus amebocyte lysate endochromek kit (Charles River Endosafe, Charleston, SC, USA) and used for transfection studies both in vitro and in vivo. Cells were plated at a density of 1 Â 10 4 cells/ml in 12-well plates 24 h before transfection. The medium was replaced with fresh medium on the day of transfection and cells were transfected with polyplexes in a total volume of 30 ml at 371C and cell growth monitored at various time points. Cells were prepared for analysis from 12 to 48 h post-transfection. The media was aspirated from each replicate well at each time point and adherent cells were stained with crystal violet and solubilized with acidified ethanol for spectrophotometric determination of cell number by OD at 595 nm.
Polyplex vector formation
The formation of SHA-PEI, in which 5% of the primary amine groups of PEI (Aldrich Chemical Company, Inc., Milwaukee, WI, USA) was replaced with SHA, was performed by Prolinx Inc., (Seattle, WA, USA). A working solution of 10 mM SHA-PEI (pH 7.4) was made in endotoxin-free water (BioWhittaker) and stored at 41C For vector formation, an a/p ratio of 2.7/1, corresponding to 4.5 ml of SHA-PEI added to 5.5 ml of 20 mM HEPES buffer was generated. bgal (6 mg) was pipetted into polystyrene tubes (Becton Dickinson) and the solution was brought up to 60 ml with HEPES buffer. Following this, 10 ml of the SHA-PEI solution was added directly to the bgal DNA solution and the solution allowed to incubate at room temperature for 5 min. After this, appropriate amounts of PDBA-PEG-J591 were added and the incubation continued for an additional 5 min, which resulted in the formation of the J591/PEG/PEI/ DNA-bgal vector (Figure 1) . The exact moles of J591 per vector was calculated using the formula by Prolinx as explained above. With this calculation, we were able to generate 1 to as high as 2835 molecules of J591 per vector. For in vitro transfection studies, 30 ml of the PEI/DNAbgal, SHA-PEI/DNA-bgal or J591/PEG/PEI/DNA-bgal vector was incubated with cells.
Photon correlation spectroscopy
The sizes and z potentials of PEI/DNA/J591 complexes before and/or after addition of PEG and dextrose were measured by photon correlation spectroscopy, also known as dynamic light scattering, using a Zeta-sizer 3000HS (Malvern, Southboro, MA, USA). The measurements were performed according to the manufacturer's instructions with the following settings: temperature, 251C scattering angle, 901 analysis mode, CONTIN by number. The results are presented as the mean7the standard deviation of at least three preparations; each preparation was measured three times. All conjugates contained 6 mg of bgal DNA and polyplex vector formation was generated as described above. The conjugates varied in both sizes and zeta potential as follows: PEI/DNA (9876.2 nm, z +5.772.1); J591/PEI/ DNA, Àdex, ÀPEG (63077.1 nm, z +2.371.9); J591/PEI/ DNA, Àdex, +PEG (68077.1 nm, z +42.372.4); J591/ PEI/DNA, +dex, ÀPEG (62274.5 nm, z +45.175.7); and J591/PEI/DNA, +dex, +PEG (80979.1 nm, z +28.573.1).
Biotin modification and internalization of J591 monoclonal antibody
To verify internalization of the J591 antibody, biotin was attached to J591 to be tested in combination with streptavidin-bgal (Sigma). About 50 mg of J591 was resuspended in 70 ml of 50 mM NaHCO 3 buffer. Following this, 4.3 ml of biotin (EZ-Link Sulfo-NHS-LC-Biotin, Pierce) in 50 mM NaHCO 3 was added to the J591 solution and the resulting reaction was incubated at room temperature for 30 min. Dialysis was then performed for 48 h with a 50 000 Mw cutoff membrane. For detection of biotin modification, a 10 mM solution of ImmunoPure HABA (Pierce) was first generated. Avidin-HABA reagent was produced by adding 8 mg of avidin and 600 ml of HABA to 19.4 ml of PBS. The absorbance of 900 ml of avidin-HABA was measured at OD 500 and used as a baseline for comparison to the solution containing Biotin-J591+avidin-HABA. About 100 ml of Biotin-J591 was heated at 651C for 10 min and added to the avidin-HABA reagent and OD 500 reading taken. The exact calculations of the number of biotin molecules attached to one molecule of J591 were performed as per the manufacturer's instructions. For internalization of J591, two polystyrene snap-top tubes of 20 ml of a 16.6 mM stock of streptavidin-bgal and 1 ml of a 6.6 mM stock of biotin-J591 combined with 29 ml of 20 mM HB were first made. Solutions were all combined and allowed to react at room temperature for 10 min. Following this, 30 ml of the reaction was dropped into each well and incubated for 1 h. Cells were trypsinized and bgal quantitation was performed as described previously. Controls were treated with HB only and competition was performed by the addition of 100-fold molar excess of free J591 to each well.
In vitro transfection and bgal analysis
Cells were plated in 12-well plates (Falcon, Becton Dickinson) in the appropriate medium 48 h prior to transfection. All incubations of the various polyplex formulations with cells were performed in 1 ml of serumfree medium for 3 h at 371C in a CO 2 incubator. After incubation, the serum-free medium was replaced with 1 ml of growth medium and cells were then incubated for 24 h at 371C The plasmid containing the E. coli bgal gene under the control of the cytomegalovirus enhancer and promoter (pCMVbgal) was isolated by an alkaline-SDS lysis method, checked for the presence of endotoxin with a limulus amebocyte lysate endochrome-k kit (Charles River Endosafe, Charleston, SC, USA) and used for transfection studies both in vitro and in vivo. Expression of bgal was determined from cells using a Galacto-light chemiluminescent reporter assay (Tropix), In vivo bgal and yellow fluorescent protein analysis Male athymic nude mice, 5-6-week-old (Harlan, Indianapolis, IN, USA) were first irradiated with 350 rads and injected orthotopically in the prostate on the same day either with 5 Â 10 6 C4-2 cells or 2.5 Â 10 5 PC3MM2 cells in 50 ml sterile PBS buffer. Tumor formation was monitored by palpation of the prostate until reaching a size of 5 Â 5 mm in 10-14 days (PC3MM2) or 2-3 weeks (C4-2). For vector formation, an a/p ratio of 2.7/1, corresponding to 4.5 ml of SHA-PEI added to 5.5 ml of 20 mM HEPES buffer, was generated. bgal, (6 mg) was pipetted into polystyrene tubes (Becton Dickinson) and the solution was brought up to 60 ml with HEPES buffer. Following this, 10 ml of the SHA-PEI solution was added directly to the bgal DNA solution and the solution allowed to incubate at room temperature for 2 min and 30 s. Consequently, 1 ml of PDBA-PEG-J591, corresponding to 756 molecules of J591 per vector, was added to the solution for another 2 min and 30 s, which resulted in the formation of the J591/PEG/PEI/DNA-bgal vector, and this was followed by 15 ml of 30% PEG to prevent general blood clearance of the vector and 7 ml of 50% dextrose to convert the vector to a more physiologically compatible solution in vivo. The total formulation in a volume of 93 ml was then injected via the tail veins of mice. Controls were injected with 70 ml of HB, 15 ml of 30% PEG and 7 ml of 50% dextrose intravenously 24 h following the injection; expression of bgal was determined in the tumor as well as the lung using a galactolight chemiluminescent reporter assay (Tropix) as described earlier. Since the aromatic ring of PDBA interferes with the function of the bicinchoninic acid in the BCA protein assay, all protein analysis of PDBA conjugates was performed using a NanoOrange protein quantitation kit (Molecular Probe). All animal experiments were conducted under institutional guidelines established for the Animal Core Facility at the MD Anderson Cancer Center.
For vector distribution studies, a plasmid expressing enhanced yellow fluorescent protein (pIRES-EYFP) (Clontech, Palo Alto, CA, USA) was used. To determine vector distribution, mice received three daily injections of the J591/PEG/PEI/DNA-YFP targeted formulation via the tail vein in a volume of 93 ml, with the ratios of J591:vector and amine a/p being similar to the bgal targeting vector described above. These multiple injections were necessary to better visualize YFP-positive cells on tumor sections. After 24 h, tumor and other tissues were removed and analyzed for fluorescence. Tissue sections (12 mm) of prostate tumors on microslides were fixed in cold acetone for 10 min. Sections were examined under an Olympus IX70 fluorescent microscope equipped with the MagnaFire software for YFP-positive cells at Â 40 magnification.
J591-mediated targeting of prostate-specific membrane antigen in neovascular endothelial cells
To determine neovascular targeting, mice received three daily injections of the biotinylated J591 as described above in the materials and methods via the tail vein in a total volume of 93 ml which included PEG and PEI. Respective tumor samples taken 24 h or 7 days after initial cell injection were all snap-frozen in OCT compound, placed in isopentane and stored at À201C. Multiple 12-mm cryostat tissue sections were then cut, mounted on aminopropylethoxysilane-treated microslides and fixed in cold acetone (41C) for 12 min. The specimens underwent 30-min incubation with a normal horse blocking serum 1:20 in 2.0% BSA. Sections were then incubated with streptavidin-linked horseradish peroxidase at room temperature for 15 min. Following washes in TBST (50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 0.1% Tween 20), a signal amplification step was performed by incubating the sections with biotinyltyramide at room temperature for 5 min. Sections were washed in TBST, and a second incubation with streptavidin-linked horseradish peroxidase was performed. Following final TBST washes, color development was performed with the diaminobenzidine chromogenic substrate, which generates a brown color.
Western immunoblot analysis
Western blot analysis was performed on lysates of 5 Â 10 4 cells. Cell samples and the SeeBlue Plus 2 protein standard (Invitrogen) were run on a 12% Gene Mate express gel for 1 h and transferred onto a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia biotech) at 50 V for 2 h. Membrane was probed with 5% milk, 1:4000 dilution of monoclonal anti-b-actin primary antibody and a 1:250 dilution of J591 overnight at 41C After washing in PBS/Tween 20, 10 ml of mouse IgG secondary antibody linked with horseradish peroxidase (Amersham pharmacia Biotech, UK) was added and incubated for 1 h. The membrane was visualized with ECL analysis system according to the manufacturer's instructions. It was then placed inside a Kodak Biomax cassette, exposed to film (ECL Hyperfilm) in the darkroom for 1 min and developed in an Exomat processor (Kodak).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay was performed in an SHA-linked polystyrene flat-bottom 96-well plate (Versalinx). Various amounts of PDBA-PEG-J591 targeting ligand were added to SHA-linked wells in triplicate, and allowed to incubate at RT for 1 h. Wells were then washed with ELISA wash and probed for 30 min with 1:1000 dilution of mouse IgG secondary antibody linked with horseradish peroxidase. After a further wash, visualization of positive interaction was confirmed via the addition of 100 ml of 3,3 0 ,5,5 0 -tetramethyl-benzidine (TMB) in sodium acetate-citrate buffer (Fujirebio Incorporated) and incubation with shaking for 30 min at RT. Assay results were measured at 450 nm using a uQuant plate reader (Bio-Tek Instruments, Inc.).
Statistical analyses
Unless noted otherwise, results from in vitro experiments represent at least two independent experiments, while 
